Can B Corp (CANB)

[sleekscape]

CANB is a CBD Oil company that has 3 revenue generating divisions — Medical CBD, Retail CBD and Medical Device CBD

Canbiola — Medical CBD

Pure Leaf — Retail CBD

Duramed — Medical Device CBD (SAM)


My DD on the company is posted here:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148005117

This is the most recent CANB interview and it is a must-listen:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148357871


The revenue growth CANB achieved during the last quarter, as well as for the full year 2018, was extremely impressive

Here are the 2018 quarterly revenues, which consisted almost entirely of Canbiola Medical CBD product sales:

Q1 — $69,000

Q2 — $154,000

Q3 — $163,000

Q4 — $281,000


The annual revenue growth was outstanding:

2017 Annual Revenue — $122,000

2018 Annual Revenue — $668,000


CANB uplisted from the pink sheets to the QB in late 2018

Even when they were on the pink sheets earlier in 2018, they still filed a fully audited and very comprehensive 175 page 10-k for 2017

The 2018 10-k is also fully audited and equally comprehensive


If you follow the CBD Oil sector, it has been a tough week for the bellwether stocks CVSI and CWBHF

CANB tends to move with the sector, so some downward price movement this week wasn’t unexpected

In addition, CANB had been trading in a range between .05-.06 for the past few weeks, and when the .05 level didn’t hold yesterday, it’s to be expected that technical traders are going to sell

I believe the combination of those 2 factors explains most of the price action we have seen in CANB this week.


I am very much looking forward to reading the Q1 10-Q that is due next week on 5/15/19

I’m excited to see what the revenues will look like, as we are getting our first taste of CBD Medical Device revenue from SAM, which launched in February

The market’s reaction to the fantastic revenue growth in Q4 was very strong — CANB doubled from .03 to .06 — and I think there is an excellent possibility that we will see a similar reaction next week

The escalating quarterly revenue growth moving forward in 2019 is the crux of the fundamental argument for investing in CANB this year

In addition, I also strongly believe that the CBD Oil sector as a whole is going to catch fire in 2019 due to the rapidly growing expansion of CBD product distribution across the country, increased awareness of CBD as an investment vehicle amongst prospective investors, and the FDA giving the greenlight to the CBD Oil industry this summer, which I have posted about extensively on my board


Sleek